argenx SE
empasiprubart
multifocal motor neuropathy (MMN)
Countdown
177days
Phase 3 readout · ~ Dec 31, 2026 estimated
What's at stake
Phase 3 trial results for empasiprubart in multifocal motor neuropathy (MMN) are due ~ Dec 31, 2026. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· SEC 6-K
verified 12h ago
“Topline results from EMVIGORATE and EMNERGIZE studies (CIDP) expected in second half of 2027”